Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Retevmo
Pharma
ASCO: Lilly tees up expansion into Retevmo’s 'final chapter’
Retevmo showed an 83% reduction in disease progression or death when used as an adjuvant therapy in early-stage RET fusion-positive lung cancer.
Zoey Becker
May 31, 2026 8:00am
Lilly's Retevmo succeeds as adjuvant treatment in NSCLC
Feb 17, 2026 11:02am
ESMO: Lilly drug drives major benefits in lung, thyroid cancers
Oct 21, 2023 10:30am
Lilly shows Roche how it's done in thyroid cancer niche
Aug 22, 2023 10:51am
Lilly pressures Blueprint further with positive NSCLC readout
Aug 4, 2023 10:40am
Roche pulls a Gavreto cancer indication, citing unfeasible trial
Jul 5, 2023 12:16pm
